Led · Equity · Jun 2024

Lyophitech develops a disruptive continuous lyophilization technology that introduces agitation during vacuum drying, contrasting with traditional static, batch plate lyophilizers. The company holds several families of proprietary patents and offers machine ranges for 7‑litre, 50‑litre and 1,000‑litre productions designed to meet GMP requirements. Its process aims to enable gentler, contact‑free confinement suitable for fragile products such as APIs, anaerobic probiotics, cytotoxic drugs, enzymes, peptides, oligonucleotides, stem cell master cells and monoclonal antibodies. Lyophitech was founded in 2017 and is based in Vénissieux, after many years of development. The firm plans to accelerate sales, with a priority on European markets, and to develop a fully automated machine tailored to the pharmaceutical industry. Management changes include the appointment of Marie‑Hélène Gramatikoff as CEO.

Participated · Grant · Oct 2021

Lys Therapeutics is developing LYS241, a fully humanized, Fc‑silent IgG1 monoclonal antibody designed to selectively block the pathological interaction between tissue plasminogen activator (tPA) and NMDA receptors while preserving physiological receptor function. The company is positioning LYS241 to address blood‑brain barrier dysfunction, neuroinflammation and excitotoxicity across Parkinson’s disease, synucleinopathies including multiple system atrophy, and ischemic stroke. Preclinical data cited by the company support potential effects on BBB dysfunction, neuroinflammation and neurodegenerative progression, and suggest relevance as a standalone or adjunctive therapy in ischemic stroke to improve reperfusion quality and reduce complications. Lys has completed preclinical, regulatory, manufacturing and translational milestones and plans a biomarker‑rich Phase 1a/1b program including healthy volunteers and indication‑specific patient cohorts. Financially, the company has raised more than €25 million since founding in 2021, including a grant of over $5 million from The Michael J. Fox Foundation and support from Bpifrance, France 2030 and private investors.